Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Arsen Osipov

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9000-7040; OpenAlex author ID A5005658250; NIH RePORTER profile ID 15656257. Sources: ClinicalTrials.gov.

Their work

Papers
45 (first author 3, last author 7)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
1
Collaborators
139
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: 1 trial · 2019: 2 papers · 2020: none · 2021: 4 papers · 2022: 8 papers · 2023: 4 papers · 2024: 12 papers · 2025: 6 papers, 1 grant · 2026: 5 papers, 1 trial

Papers 45

  1. Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization. Co-author DOI 10.1002/pon.70601↗
  2. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  3. L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 Glut… Co-author DOI 10.1038/s43018-026-01225-z↗
  4. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  5. Implications of Homologous Recombination Deficiency for Neoadjuvant Platinum-Based Chemotherapy in Pancreatic Cancer: A Narrative Review. Co-author DOI 10.1245/s10434-025-19056-0↗
  6. Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directed care. Last author DOI 10.1016/j.hpb.2025.07.012↗
  7. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. Last author DOI 10.1093/oncolo/oyaf007↗
  8. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Last author DOI 10.1158/1078-0432.ccr-24-3403↗
  9. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  10. Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. Co-author DOI 10.1200/po-24-00684↗
  11. HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver. Co-author DOI 10.7150/ijbs.102132↗
  12. Accuracy of Clinical Staging in Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jama.2024.16332↗
  13. Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation T… Co-author DOI 10.1016/j.adro.2024.101471↗
  14. Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells. Co-author DOI 10.1016/j.freeradbiomed.2024.01.003↗
  15. High frequency of germline variants in CFTR identified in PDAC patients enrolled in an expanded panel multi-gene panel testing program. Last author DOI 10.1016/j.hpb.2024.05.005↗
  16. Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. Co-author DOI 10.1038/s41698-024-00521-0↗
  17. The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s43018-023-00697-7↗
  18. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
  19. Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. Co-author DOI 10.1186/s13045-024-01576-z↗
  20. Ascites Is a Poor Prognostic Factor in Advanced Pancreatic Adenocarcinoma and May Be Undertreated: A Prospective Cohort Study. Co-author DOI 10.14309/ctg.0000000000000719↗
  21. A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy. Co-author DOI 10.18632/oncotarget.28659↗
  22. Fecal Microbiome Composition and Plasma Metabolomics in Pancreatic Cancer Cachexia Treated with Nutritional Support Co-author DOI 10.20944/preprints202401.0727.v1↗
  23. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analy… Co-author DOI 10.3390/cancers16050971↗
  24. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001-2018. Co-author DOI 10.1053/j.gastro.2023.01.022↗
  25. Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol. First author DOI 10.3390/biomedicines11051392↗
  26. Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000-2018. Co-author DOI 10.3390/cancers15030870↗
  27. Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15113020↗
  28. Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Co-author DOI 10.1016/j.canlet.2022.215722↗
  29. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
  30. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. Last author DOI 10.1016/j.pan.2021.09.015↗
  31. Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-19401-3↗
  32. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-23619-6↗
  33. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Last author DOI 10.1053/j.gastro.2022.06.027↗
  34. Gut microbiome and pancreatic cancer cachexia: An evolving relationship. Co-author DOI 10.4251/wjgo.v14.i7.1218↗
  35. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7039↗
  36. Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. Co-author DOI 10.1002/jcsm.12799↗
  37. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  38. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. Co-author DOI 10.20892/j.issn.2095-3941.2020.0273↗
  39. Advances in Pancreatic Ductal Adenocarcinoma Treatment. Last author DOI 10.3390/cancers13215510↗
  40. Dual Checkpoint Inhibition in Pancreatic Cancer: Revealing the Limitations of Synergy and the Potential of Novel Combinations. Co-author DOI 10.1001/jamaoncol.2019.1583↗
  41. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2018.12.060↗
  42. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. Co-author DOI 10.1245/s10434-017-6076-z↗
  43. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. First author DOI 10.21037/jgo.2016.12.04↗
  44. Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. First author DOI 10.1371/journal.pone.0152172↗
  45. Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. Co-author DOI 10.3978/j.issn.2078-6891.2015.109↗

Trials 2

  1. Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma Principal investigator NCT06981806↗
  2. GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer Principal investigator NCT03161379↗

Grants 1

  1. Targeting the Stroma for Pancreatic Cancer Treatment K08CA259456↗

Closest collaborators

The 25 strongest of 139 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Eugene Hendifar · 31 shared papers, 2016–2026 · strength 5.05
  2. Jun Gong · 20 shared papers, 2021–2026 · strength 3.51
  3. Stephen Jacob Pandol · 13 shared papers, 2021–2026 · strength 2.28
  4. Simon K. Lo · 13 shared papers, 2019–2026 · strength 2.14
  5. Srinivas Gaddam · 10 shared papers, 2022–2026 · strength 1.86
  6. Nicholas N. Nissen · 14 shared papers, 2016–2025 · strength 1.84
  7. Lei Zheng · 10 shared papers, 2021–2026 · strength 1.42
  8. Brent K. Larson · 7 shared papers, 2022–2026 · strength 1.36
  9. Natalie Moshayedi · 8 shared papers, 2022–2026 · strength 1.28
  10. Neil A. Bhowmick · 6 shared papers, 2022–2026 · strength 1.11
  11. Daniel A. Laheru · 6 shared papers, 1 shared trial, 2018–2026 · strength 1.10
  12. Abrahm Levi · 5 shared papers, 2023–2026 · strength 1.01
  13. Hayato Muranaka · 5 shared papers, 2022–2026 · strength 0.90
  14. Veronica Placencio-Hickok · 6 shared papers, 2019–2024 · strength 0.86
  15. Keyu Li · 6 shared papers, 2021–2024 · strength 0.76
  16. Cristina Rosa Ferrone · 3 shared papers, 2024–2026 · strength 0.76
  17. Robert A. Anders · 5 shared papers, 2021–2026 · strength 0.74
  18. Elizabeth M. Jaffee · 5 shared papers, 2021–2026 · strength 0.74
  19. Nan Niu · 5 shared papers, 2021–2024 · strength 0.66
  20. Michael Jon Pishvaian · 3 shared papers, 2025–2026 · strength 0.66
  21. Amol Kumar Narang · 4 shared papers, 2022–2026 · strength 0.65
  22. Omer Hany Miligy Elmadbouh · 3 shared papers, 2024–2026 · strength 0.64
  23. Mouad Edderkaoui · 3 shared papers, 2024–2026 · strength 0.64
  24. Matthew Ebia · 3 shared papers, 2025 · strength 0.64
  25. Richard Andrew Burkhart · 4 shared papers, 2021–2026 · strength 0.61

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.